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The Tumor Suppressor Gene Brca1
Is Required for Embryonic Cellular
Proliferation in the Mouse
Razqallah Hakem,1,2 Jose´ Luis de la Pompa,1,2 and dietary factors are known to contribute to breast
cancer risk, family history is also an important factor.Christian Sirard,1,2 Rong Mo,3,5 Minna Woo,1,2
Anne Hakem,1,2 Andrew Wakeham,1,2 Breast cancer susceptibility genes such as BRCA1 (Hall
et al., 1990; Miki et al., 1994) and BRCA2 (Wooster etJulia Potter,1,2 Armin Reitmair,1,2 Filio Billia,2
Eduardo Firpo,6 Chi Chung Hui,3,5 Jim Roberts,6 al., 1994, 1995; Tavtigian et al., 1996) have been recently
identified and cloned.Janet Rossant,3,4,7 and Tak W. Mak1,2
1 Amgen Institute A large number of mutations in the BRCA1 gene have
been reported in families with predisposition to both2Ontario Cancer Institute
Department of Medical Biophysics and Immunology inherited and sporadic breast and ovarian cancers (Cas-
tilla et al., 1994; Friedman et al., 1994; Futreal et al.,University of Toronto
Toronto, Ontario M5G 2C1 1994; Miki et al., 1994; Merajver et al., 1995a; Hosking
et al., 1995). Manifestation of the disease is associatedCanada
3Department of Molecular and Medical Genetics with the loss of the wild-type BRCA1 allele (Futreal et
al., 1994; Cornelis et al., 1995; Merajver et al., 1995b),4Department of Obstetrics and Gynecology
University of Toronto suggesting that BRCA1 is a tumor suppressor gene.
The BRCA1 gene contains 22 coding exons and en-5Program in Developmental Biology
Division of Endocrinology Research Institute codes a 1863 amino acid protein with an amino-terminal
Cys3-His-Cys4 zinc finger and a carboxy-terminal acidicThe Hospital for Sick Children
Toronto, Ontario M5G 1X8 domain (Miki et al., 1994). Missense mutations in the
BRCA1 zinc finger domain at cysteines 61 and 64 haveCanada
6Department of Basic Sciences been reported in inherited breast cancer and sporadic
ovarian cancer (Castilla et al. 1994; Friedman et al., 1994;Fred Hutchinson Cancer Research Center
1124 Columbia Street Miki et al., 1994; Merajver et al., 1995a), suggesting a
critical role for the zinc finger domain in the BRCA1Seattle, Washington 98104
7Samuel Lunenfeld Research Institute function. The nuclear localization of BRCA1 as reported
in two studies (Chen et al., 1995; Rao et al., 1996) andMount Sinai Hospital
Toronto, Ontario M5G 1X5 the presence of a zinc finger domain and a carboxy-
terminal acidic domain suggest that this tumor sup-Canada
pressor protein may act as a transcriptional regulator.
Paradoxically, however, a recent report suggests the
possibility that the BRCA1 protein might be secretedSummary
(Jensen et al., 1996).
Brca1, the mouse homolog of BRCA1 located onchro-Mutations of the BRCA1 gene in humans are associ-
mosome 11, encodes a 1812 amino acid protein (Laneated with predisposition to breast and ovarian can-
et al., 1995). The Brca1 protein shows an overall 58%cers. We show here that Brca11/2 mice are normal
amino-acid identity to the human homolog, and the zincand fertile and lack tumors by age eleven months.
finger domain is conserved. Brca1 mRNA is expressedHomozygous Brca15-6 mutant mice die before day 7.5
in several adult tissues, including breast, ovary, thymus,of embryogenesis. Mutant embryos are poorly devel-
and testis (Lane et al., 1995; Marquis et al., 1995). In situoped, with no evidence of mesoderm formation. The
hybridization analysis has shown that Brca1 is ex-extraembryonic region is abnormal, but aggregation
pressed at 9.5 days and later stages of embryogenesiswith wild-type tetraploid embryos does not rescue the
(Lane et al., 1995; Marquis et al., 1995). Little is knownlethality. In vivo, mutant embryos do not exhibit in-
about Brca1 expression during earlier embryonic devel-creased apoptosis but show reduced cell proliferation
opment, and its normal function in the adult, as well asaccompanied by decreased expression of cyclin E and
during embryogenesis, remains to be defined.mdm-2, a regulator of p53 activity. The expression of
To investigate the biological function of Brca1 in vivocyclin-dependent kinase inhibitor p21 is dramatically
and tocreate a mouse model to study breast and ovarianincreased in the mutant embryos. Buttressing these
cancer, we generated a Brca1 mutant mouse by deletingin vivo observations is the fact that mutant blastocyst
exons 5 and 6 of the Brca1 coding region. Analysis ofgrowth is grossly impaired in vitro. Thus, the death of
Brca15-6 mutant embryos in vivo and in vitro suggestsBrca15-6 mutant embryos prior to gastrulation may be
that Brca1 may be involved in the control of the prolifera-due to a failure of the proliferative burst required for
tive process that occurs in early embryonic devel-the development of the different germ layers.
opment.
Introduction Results
Generation of Brca15-6 Mutant MiceBreast carcinoma is the most common female cancer.
In western societies, one in ten women will develop the The Brca1 gene in embryonic stem (ES) cells was dis-
rupted using a targeting vector in which exons 5 and 6disease inher lifetime. Although reproductive,hormonal,
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of Brca1 were deleted, leading to the introduction of
termination codons in all three reading frames and the
removal of the zinc finger domain (see Experimental
Procedures). The neomycin resistance (neo) gene was
inserted in the targeting vector in the opposite orienta-
tion to Brca1, such that neo was flanked by 0.6 kb of
genomic DNA 59 of Brca1 exon 5 and 7 kb of genomic
DNA 39 of Brca1 exon 6 (Figure 1A). When this targeting
construct was electroporated into ES cells, 4 out of 1152
G418-resistant colonies analyzed by polymerase chain
reaction (PCR) and Southern blotting wereheterozygous
for the Brca1 locus. Two of these ES clones were used
to generate chimeric mice, and both successfully con-
tributed to the germ line.
The chimeras were backcrossed to C57BL/6J, CD1,
or C3H/HeJ mice, and heterozygotes were crossed to
produce homozygous mutant offspring. The genotypes
of the mice were confirmed by Southern blot analysis.
Phenotype of Heterozygote Brca15-6 Mice
Humans heterozygous for the BRCA1 mutation are esti-
mated to have, by age 60, a penetrance of z50% for
breast cancer and z30% for ovarian cancer (Easton et
al., 1993; Ford et al., 1994). Mice heterozygous for the
Brca15-6 deletion were phenotypically normal and fertile.
By eleven months of age, heterozygote Brca15-6 females
did not show any type of cancer. However, it remains
possible that these Brca15-6 heterozygote mice may de-
velop tumors at a more advanced age.
Brca15-6 Mutation Results in Early
Embryonic Lethality
No viable Brca15-6 pups were identified among 88 off-
spring born from heterozygous intercrosses, indicating Figure 1. Targeted Disruption of the Brca1 Locus
that homozygosity for the Brca15-6 mutation causes em- (A) A portion of the mouse Brca1 wild-type locus (top) showing
bryonic lethality (Figure 1B; Table 1). exons 5–10 (open boxes) and HindIII sites. Closed boxes represent
the 59 arm and the 39 arm of the targeting construct. The 4.3 kbTo assess the consequences of the Brca15-6 mutation
HindIII fragment present in the wild-type allele and the PCR primerson embryonic development, we analyzed embryos from
“a” and “b” used to identify the wild-type allele are shown. Theheterozygote intercrosses at different days of gestation
targeting vector (middle) and the position of the neomycin resistance
(Table 1). Genomic DNA was isolated from yolk sacs or gene (neo), oriented in the opposite orientation to Brca1 gene tran-
from whole embryos, and genotyping was performed scription. The targeting vector was designed such that the neo
by PCR amplification using primers a, b, c,and d (Figures cassette replaced exon 5 and exon 6 of the Brca1 gene. The mutated
Brca1 locus (bottom) showing the 2.6 kb HindIII DNA fragment pres-1A and 1C). Degenerating or resorbed embryos were
ent in the recombinant Brca1 allele. The position of the 59 flankingobserved at E7.5 and E8.5 and were genotyped as
probe used for Southern blot analysis and the PCR primers “c” andBrca15-6 homozygotes. At E6.5, z25% of all embryos
“d” used to identify the mutated allele are shown.
were morphologically abnormal; these were also geno- (B) Southern blot analysis of representative genomic tail DNA from
typed as mutants. Mutant E6.5 embryos could be cate- one litter of Brca15-6 heterozygous intercrosses. DNA was digested
gorized into two phenotypic classes according to the with HindIII and hybridized with 59 external probe. The 4.3 kb band
representative of the wild-type allele (wt) and the 2.6 kb band repre-severity of their phenotype (Figures 2A–2D). Embryos in
sentative of the mutated allele (mt) are indicated by arrows.the less severely affected class were less than half the
(C) Representative genotypic analysis of E6.5 embryos from a Brca1size of their wild-type E6.5 littermates and showed no
heterozygous breeding. DNA samples were subjected to PCR using
clear boundary between the embryonic and the extra- the primer pairs a/b or c/d (see Experimental Procedures for se-
embryonic regions (Figures 2A–2B). The more severely quences). PCR amplification of the mutated Brca1 gene allele by
affected class contained embryos that resembled egg- primer pair c/d produced a 616 bp DNA fragment (upper panel),
while PCR amplification of the wild-type Brca1 gene allele by primercylinders, with no morphological organization (Figures
pair a/b produced a 353 bp DNA fragment (lower panel).2C and 2D). By E7.5, mutant embryos showed no in-
crease in size and were beginning to be resorbed (Fig-
ures 2E and 2F).
Mutant mice generated from the two independent tar- Brca15-6 allele results in embryonic lethality before E7.5
and indicate that Brca1 is essential for postimplantationgeted ES cell clones showed identical phenotypes.
These results demonstrate that homozygosity for the development at the time of initiation of gastrulation.
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Table 1. Genotypic and Phenotypic Analysis of Neonates and Embryos from Brca15-6 Heterozygous Intercrosses
Phenotype Genotype
Stage Normal Abnormal Brca11/1 Brca11/2 Brca12/2 Total
Neonate 88 0 27 61 0 88
E8.5 11 6 2 9 6 17
E7.5 13 2 2 11 2 15
E6.5a 25 9 6 19 9 34
Neonates were genotyped by Southern blot analysis using the 59 flanking probe as shown in Figure 1B. The embryos were collected on days
8.5, 7.5, and 6.5 of pregnancy from Brca15-6 heterozygous females crossed to Brca15-6 heterozygous males. The embryo genotypes were
determined by PCR amplification using DNA extracted from the whole embryo or from the yolk sac, and primers a, b, c, and d as shown in
Figure 1C. Homozygous mutant embryos exhibited an abnormal phenotype, characterized by poor embryonic organization and a reduced
size in comparison with normal-looking control littermates.
a In the histological analysis, whole litters were analyzed. E6.5 embryos were classified phenotypically into two categories, wild type (126
embryos) and mutant (46).
Histological Analysis of the Brca15-6 experiments using cDNA from ES and E7.5 cells con-
firmed the presence of the Brca1 exon 11 negative tran-Mutant Embryos
The structural organization of Brca15-6 mutant embryos script. Primers specific for Brca1 exons 9 and 13 could
amplify the 352 bp product expected if Brca1 exon 11was characterized in greater detail by histological analy-
sis of serially sectioned E5.5–E6.5 embryos obtained is spliced out. Southern blot hybridization showed that
the 352 bp PCR product contains both Brca1 exons 10from heterozygous crosses (Figures 3A–3E). Upon ex-
amination of E5.5 egg cylinder–stage embryos (Figures and 12 (Figure 4C). The existence of a transcript in which
Brca1 exons 5 and 6 were spliced out was also ad-3A and 3B), two phenotypes were obvious, one normal
and the other abnormal. Smaller, poorly organized, ab- dressed by PCR amplification of cDNAs from ES and
E7.5 cells, using Brca1 primers specific for exons 3 andnormal embryos could be readily distinguished (Figure
3B) among their wild-type littermates (Figure 3A). At 7. A 328 bp product was amplified, the size expected if
exons 5 and 6 were not spliced out. The specificity ofE6.5, phenotypic differences between wild-type and
mutant embryos became even more apparent (Figures this product and the presence of Brca1 exons 5 and 6
in all Brca1 transcripts was further confirmed by PCR3C–3E). Wild-type embryos exhibited a well-organized
ectoderm and endoderm (Figure 3C) while the mutant Southern blot analysis using primers specific for exon
5 and exon 6 (Figure 4C).embryos (z25% of all embryos) showed an abnormal
organization and could be grouped into two phenotypi- Thus we show, in ES cells and during embryogenesis,
the coexistence of Brca1 exon 11 negative and Brca1cally mutant classes. Embryos in the less severe class
showed epiblast, no detectable primitive streak, a very exon 11 positive transcripts. However, more importantly
we show that no Brca1 exon 5 and exon 6 spliced formthin visceral and parietal endoderm, and a proamniotic
cavity. In addition, theextraembryonic region was poorly is detected.
Two approaches were used to investigate whetherorganized with no compact diploid core of trophoblast
cells (Figure 3D). Embryos with the more severe mutant the gene targeting of the Brca1 locus resulted in a null
mutation. First, individual preimplantantion embryos atphenotype exhibited few ectoderm cells and no detect-
able extraembryonic region (Figure 3E). The most devel- E2.5 (B2.5) and E4 (B4) were genotyped and their total
cDNAs amplified by PCR in an unbiased fashion (seeoped E6.5 mutant embryos did not appear to progress
significantly beyond E5.5. Interestingly, the time of the Experimental Procedures). Two of the ten B2.5 and one
of the eight B4 PCR genotyped embryos examined wereapparent developmental block of Brca15-6 mutant em-
bryos coincides with the dramatic increase in size that homozygous for the Brca15-6 mutation (data not shown).
Southern blot analysis of the amplified cDNAs using 39occurs at E5.5–E6.5 of mouse development (Snow,
untranslated (39 UTR) probes showed that Brca1 was1977).
not expressed in the homozygous mutant blastocysts
(Figure 4D). However, a ribosomal housekeeping gene,
L32, was strongly expressed in the wild type, as well as
Alternative Splicing of Brca1 Exon 11 in the homozygous mutant.
Northern blot analysis using a Brca1 Exon 11 probe In the second approach, the spatial expression of
showed the expression of a Brca1 transcript (over 7 kb) Brca1 in E6.5 wild-type and mutant embryos was ana-
in ES cells and in E7.5, E8.5, E9.5, and E10.5 embryos lyzed by in situ hybridization in tissue sections, using
(Figure 4A). Northern blot experiments using a probe for an antisense Brca1 exon 11 probe. Brca1 transcripts
Brca1 exons 7–9 indicated the presence, in ES cells and could be detected homogeneously throughout the epi-
inE7.5, E8.5, E9.5, and E10.5, of a Brca1 exon 11 positive blast, developing mesoderm and extraembryonic re-
transcript (7.2 kb) together with a smaller Brca1 tran- gions (Figures 5A and 5B). Mutant embryos failed to
script (z2 kb) (Figure 4B). The small Brca1 transcript show any expression of Brca1 transcript (Figures 5C
was not detected with the exon 11 probe, indicating the and 5D).
These results indicate that the Brca15-6 mutation is aexistence of Brca1 exon 11 negative transcripts. PCR
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Figure 2. Morphology of Brca15-6 Mutant Embryos
Whole-mount preparations at E6.5, egg-cylinder (A–D), and E7.5, late streak (E and F) stages.
(A and B) At E6.5, two mutant classes can be distinguished. The less severe class is represented by the embryo shown in the left part of (A).
This embryo is smaller than its wild-type littermate, although it is relatively well organized (B).
(C and D) The left part of (C) shows a severely affected mutant embryo. It is a compacted egg cylinder, much smaller than the wild-type
embryo, with no signs of organization (D).
(E and F) At E7.5, the wild-type embryo is well advanced in gastrulation. In (E) the size difference between wild-type (left) and mutant (right)
embryos can be appreciated. High magnification (F) of E7.5 Brca15-6 mutant. At this stage, mutant embryos are being resorbed and appear
surrounded by maternal tissues.
In (A), (B), (C), and (E), the arrows point to the separation between embryonic and extraembryonic regions. n, node; ps, primitive streak. Bar,
70 mm in (A) and (C); 140 mm in (B); 20 mm in (D); 100 mm in (E); and 50 mm in (F).
null mutation. Furthermore, Brca1 appears to be ex- alized cellular defect resulting in growth failure, or by
pressed throughout early embryogenesis. lineage-specific defects. Brca15-6 mutants showed par-
ticularly abnormal development of the extraembryonic
region, with absence of diploid trophoblast and appar-Brca15-6 Mutant Embryos Show Defective
ent abundance of giant cells. The expression analysisTrophoblast Development and Do
of the early trophoblast lineage marker Mash-2 con-Not Form Mesoderm
firmed this phenotype. This gene is expressed in theDeath at early postimplantation stages in Brca15-6 mu-
tant embryos could be explained either by some gener- wild-type embryo throughout preimplantation develop-
Brca1 Is Required for Embryonic Cell Proliferation
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Figure 3. Histological Analysis of Brca15-6 Mutant Embryos at E5.5 and E6.5
Sagittal sections. (A and C) Wild-type embryos; (B, D, and E) mutant embryos.
(A) E5.5 wild-type embryo. Early egg cylinder.
(B) Mutant embryo at E5.5 (arrow). The embryo is small and disorganized.
(C) E6.5 wild-type embryo. Egg-cylinder stage.
(D) Less severe mutant phenotype at E6.5. The embryo is small, with a thick ectoderm, a very thin endoderm, and an abnormal extraembryonic
region.
(E) More severe mutant phenotype at E6.5. The embryo (arrow) is completely disorganized.
In (A) and (D), the arrow points to the separation between embryonic and extraembryonic regions. d, decidua; ee, embryonic ectoderm; eee,
extraembryonic ectoderm; epc, ectoplacental cone; m, mesoderm; pa, proamniotic cavity; pe, parietal endoderm; ve, visceral endoderm. Bar,
60 mm.
ment. In wild-type E6.5 embryos, Mash-2 is expressed Morphological and histological criteria suggested that
mesoderm was also missing in Brca15-6 mutantembryos.in the diploid trophoblast lineage (Figures 5E and 5F)
but not in the trophoblast giant cells. No Mash-2 tran- To determine at the molecular level if mesoderm was
being formed in mutant embryos, we examined the ex-script was detected in Brca15-6 E6.5 mutant embryos
after in situ hybridization (Figures 5G and 5H), sug- pression of the Brachyury (T) protein by immunohisto-
chemistry in tissue sections. In wild-type E6.5 embryos,gesting the absence of diploid trophoblast cells.
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Morulas from heterozygous intercrosses were aggre-
gated with 4-cell stage wild-type CD1 tetraploid em-
bryos. In such aggregates, the wild-type tetraploid cells
are able to produce trophoblast and primitive endoderm
lineages. Embryos from the aggregates were genotyped
by PCR at day 10.5 of gestation because this time point
was appropriate to determine if wild-type extraembry-
onic tissues rescued the lethality of Brca15-6 mutant em-
bryos. From a total of 19 embryos, 15 embryos with
normal morphology were genotyped as wild-type or as
heterozygous, and four severely abnormal, degenerat-
ing embryos were found to be homozygous for the
Brca15-6 mutation. These results suggest that the extra-
embryonic defect observed in the Brca15-6 homozygous
embryos is not the sole cause of their early lethality.
Brca15-6 Mutation Does Not Affect Apoptosis
To determine if the growth deficit of Brca15-6 mutant
embryos could be accounted for by an excess of pro-
grammed cell death, serially sectioned E6.5 embryos
were analyzed by Hoechst staining and TUNEL assay
(Gavrieli et al., 1992). At this stage of development, mor-
Figure 4. Expression of Brca1 Gene in Wild-Type and Mutant phological abnormalities were obvious but the mutant
Brca15-6 Embryos embryos were not yet degenerating. Staining with
(A and B) Northern blot analysis of total RNA prepared from ES Hoescht dye revealed only a few apoptotic nuclei in the
cells and from wild-type embryos at 7.5, 8.5, 9.5, and 10.5 days of proamniotic cavity of mutant embryos (data not shown).
gestation. Hybridization with 32P-labeled exon 11 Brca1 probe (A) Coucouvanis and Martin (1995) have suggested that
detected strong expression of the Brca1 gene in ES cells and in all
these apoptotic nuclei are the cellular debris generatedanalyzed stages of embryonic development. (B) Hybridization with
in the process of cavitation.32P-labeled Brca1 exon 7–9 probe showed two forms of Brca1 tran-
scripts (Brca1 exon 111 and Brca1 exon 112 transcripts). A probe The results obtained by Hoechst staining were con-
to b-actin was used as a control for sample loading. firmed using a TUNEL assay. A few TUNEL-positive nu-
(C) Brca1 alternatively spliced transcripts during embryogenesis. clei close to the proamniotic cavity could be detected
PCR amplification of Brca1 exons 3–7 and exons 9–13 was per-
in both wild-type and mutant embryos (data not shown),formed using ES cells and E7.5 cDNA as described in Experimental
and no significant differences were detected. These re-Procedures. The ethidium bromide–stained agarose gel shows the
352 bp and 328 bp PCR products resulting from the amplification sults indicate that no excess of apoptosis occurs in
of exons 9–13 and exons 3–7, respectively. The 328 bp exons 3–7 Brca15-6 mutant embryos.
PCR product hybridized specifically with the Brca1 exon 5 and exon
6 probes, while the 352 bp exons 9–13 PCR product hybridized
with the Brca1 exon 10 and exon 12 specific probes, indicating the
Brca15-6 Mutation Decreases Embryonicexistence of exon 11 spliced transcript forms in both ES and E7.5
Cell Growthcells.
(D) Detection of Brca1 expression in PCR-amplified total cDNAs To study directly the effects of the Brca15-6 mutation on
from wild-type and mutant preimplantation embryos. Blots of PCR- cellular proliferation, we examined the incorporation of
amplified cDNA from E2.5 and E4.0 embryos were hybridized with 5-bromo-29-deoxyuridine (BrdU) into DNA during the S
a 39 UTR probe from the Brca1 gene. In contrast to the wild-type,
phase of the cell cycle. Analysis was performed at E6.5,no Brca1 expression was detected in the E2.5 and E4.0 mutant
the time at which gastrulation initiates and when theembryos. A probe containing the 39 UTR of the ribosomal
housekeeping gene L32 was used as a control for the cDNA amplifi- highest mitotic activity has been observed in the mouse
cation. embryo (Snow, 1977). Whole litters were serially sec-
tioned and phenotypes classifiedas wild type or mutant.
A mitotic index showing the ratio between proliferating
cells (BrdU-positive nuclei) and total cell number wasthe Brachyury protein is expressed in the primitive
made. Wild-type embryos show an index of 0.7–0.8,streak (Figure 5I). No signal was detected in mutant
while mutant embryos show an index between 0.4 andembryos (Figure 5J), further confirming that Brca15-6 mu-
0.5. As exemplified in Figure 6A, nuclei in 70%–80% oftant embryos fail to form mesoderm.
epiblast cells from 57 phenotypically wild-type embryos
were strongly positive for BrdU staining after 1 hr expo-
Wild-Type Extraembryonic Tissue Does Not sure. However, all 15 mutant embryos analyzed showed
Rescue the Brca15-6 Mutant Phenotype z50% nuclear staining. Furthermore, the level of BrdU
Since the most dramatic early defect in Brca15-6 mutant incorporation in the mutants was significantly weaker
embryos occurred in their trophoblast lineages, it was than in wild-type embryos (Figures 6B and 6C). Thus,
determined whether later embryonic deficiencies were BrdU incorporation is quantitatively and qualitatively af-
fected in the mutant embryos. These results indicatesecondary to a failure of trophoblast–uterine interaction.
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Figure 5. Spatial Expression of Brca1, Mash-2, and Brachyury in E6.5 Brca15-6 Mutant Embryos
In situ hybridization, bright-field (A, C, E, and G) and dark-field views (B, D, F, and H). Sagittal sections showing Brca1 (A–D), Mash-2 (E–H),
and Brachyury (I and J) expression.
(A and B) Brca1 expression in a E6.5 wild-type embryo. Sections were hybridized with an antisense Brca1 exon 11 probe. Brca1 is expressed
ubiquituosly. No signal was detected with a sense-strand probe on an adjacent section to A (data not shown).
(C and D) Mutant embryo. No Brca1 expression is detected. In (A) and (C), the arrow points to the separation between embryonic and
extraembryonic regions.
(E and F) Mash-2 expression in a E6.5 wild-type embryo. Strong expression is detected in the diploid trophoblast of the extraembryonic region
of the embryo (arrow in [E]).
(G and H) Mash-2 expression in a Brca15-6 mutant embryo. No signal is detected in the extraembryonic region (arrow in [G]).
(I and J) Immunohistochemical analysis of Brachyury expression. (I) Wild-type embryo. Arrow points to the Brachyury-positive cells in the
nascent streak. (J) Mutant embryo. No expression is detected.
Bar, 60 mm.
that proliferative capabilities of Brca15-6 mutant embryos against cyclin E and cyclin A were used to stain serially
sectioned E6.5 embryos.are severely impaired at E6.5.
To confirm this finding, we characterized the expres- Cyclin E was expressed in a large proportion (80%) of
epiblast cells from 28 phenotypically wild-type embryos.sion of regulatory proteins of cell-cycle progression in
the developing embryo. Cyclin E and cyclin A were cho- The expression of cyclin E was markedly pronounced
in the extraembryonic region, particularly in the tropho-sen, because the levels of these molecules change dra-
matically at specific points in the cell cycle. Cyclin E blast cells (Figure 6D), correlating with the results of
the BrdU analyses. However, in the 10 mutant embryosexpression peaks at theG1/S transition (Koff et al., 1992)
and has been shown to control the ability of cells to analyzed, a lower proportion (50%–60%) of epiblast
cells were positive for cyclin E. The signal was alsoenter the S phase (Ohtsubo and Roberts 1993; Ohtsubo
et al., 1995). Cyclin A expression peaks in late G2 phase weak, although staining of the trophoblast giant cells
was comparable to that of their wild-type littermatesand decreases toward mitosis. Affinity-purified antisera
Cell
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Figure 6. In Vivo Proliferation and Cell Cycle Alterations in E6.5 Brca15-6 Mutant Embryos
(A–C) BrdU incorporation; (D–F) Cyclin E expression. Sagittal sections. Positive nuclei are stained darkly. Unlabeled nuclei appear pale or
white.
(A) Wild-type E6.5 embryo. Strongly BrdU-positive nuclei can be seen throughout the embryo. Thick arrow points to strongly positive cell in
the ectoderm.
(B) Mutant Brca15-6 embryo. The large arrow points to weakly positive cells in the embryo. The small arrow points to strongly positive giant
cells.
(C) More severe mutant Brca15-6 embryo. The small arrow points to the positive cells in the extraembryonic region. Few positive cells are
detected in the embryo proper (large arrow).
(D) E6.5 wild-type embryo. Cyclin E expression is detected throughout the embryo and is particularly strong in the extraembryonic region
(thick arrow).
The severity of the Brca15-6 mutant phenotype is paralleled by the levels of cyclin E expression:
(E) Less severe mutant Brca15-6 embryo. Positive cells are seen in the embryo (large arrow). In the extraembryonic region, giant cells (small
arrow) are strongly positive.
(F) More severe Brca15-6 phenotype. Weakly positive cells are seen in the embryo (large arrow) and strongly positive cells in the trophoblast
giant cells (small arrow).
(G) E6.5 wild-type embryo. Cyclin A expression is ubiquitous throughout the embryo.
(H) Mutant Brca15-6 embryo. No major changes in cyclin A expression compared with the wild type are observed.
Abbreviations as in Figure 3. Bar, 60 mm.
(Figures 6E and 6F). It should be noted that trophoblast Expression of mdm-2, p53, and p21 in the
Mutant Embryoscells do not divide, only endoreduplicate their DNA.
No apparent differences in the level of cyclin A expres- The reduced BrdU incorporation and cyclin Eexpression
observed in Brca15-6 mutant embryos was consistentsion were detected between wild-type (Figure 6G) and
Brca15-6 mutant embryos (Figure 6H), indicating that the with an increase in the length of the mutant cell cycle,
possibly due to a defect in the G1/S transition. Mutationmutant embryos do not have a specific block in cell
cycle progression during the G2 phase. of the mdm-2 proto-oncogene, a negative regulator of
the tumorsuppressor p53 (Momand et al., 1992), leads toThe decreased Brca15-6 embryo size apparent at E6.5
is consistent with the impaired proliferative capability embryonic lethalitybefore gastrulation with a phenotype
reminiscent of Brca15-6 mutants (Jones et al., 1995; Mon-observed in mutant epiblast cells. Gastrulation initiates
at about E6.5, and a dramatic increase in cell prolifera- tes de Oca Luna et al., 1995). The p53 protein blocks cell
cycle progression at the G1 phase, and thus, mutation oftion occurs in normal embryos. It is possible that one
of the causes of mutant embryo demise at about E7.5 mdm-2 results in a block of cell proliferation that causes
early embryonic lethality. The absence of p53 activityis the inability of Brca15-6 mutants to proliferate at the
required rate. rescues the lethality of the mdm-2
Brca1 Is Required for Embryonic Cell Proliferation
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while the very weak expression of p27 (another cdk
inhibitor) was not affected (data not shown). In situ ex-
periments confirmed the highly significant increase in
p21 expression in the mutant E6.5 compared with the
wild-type (data not shown).
Brca15-6 Mutation Affects Inner Cell Mass
Proliferation In Vitro
To directly determine the growth capability of mutant
Brca15-6 embryos, E3.5 blastocysts from heterozygous
matings were collected and cultured individually in vitro.
Mutant blastocysts showed a normal phenotype, indi-
cating that the Brca15-6 mutation does not affect preim-
plantation development (Figures 8A and 8C). After 3
days in culture, both mutant and wild-type blastocysts
produced trophoblast giant cell outgrowths (Figures 8B
and 8D). However, the inner cell mass (ICM) did not
grow in 41% of the mutant blastocysts, compared with
failure in only z15% of wild-type and heterozygous blas-
tocysts (Figure 8; Table 2). Longer periods of blastocyst
culture confirmed the inability of homozygous Brca15-6
mutant cells to grow in vitro. After 10 days in culture,
only one of 24 recovered blastocyst outgrowths was
found to be homozygous for the Brca15-6 mutation. This
mutant had not developed any ICM, only trophoblast
giant cells (data not shown). In addition, numerous at-
tempts to generate Brca15-6 homozygous mutant ES
cells by increasing G418 concentration, or by using a
second targeting vector with a hygromycin resistance
cassette, were unsuccessful (data not shown). These
results from in vitro experiments directly support a gen-
eralized failure in cellular proliferation in Brca15-6 mu-
tants.
Figure 7. Brca15-6 Mutant Embryos Show Decreased mdm-2 Ex-
pression and Increased p21 Expression
The expression of p53 and its negative regulator mdm-2 was ana- Discussion
lyzed in Brca15-6 mutants using blots of total cDNA made from E2.5
(A) and E4 (B) single embryos (see Experimental Procedures). The The Brca15-6 Mutant Phenotype
blots were hybridized to 39 UTR probes specific for mdm-2, p53 or In this study, we have generated a null mutation of the
L32 (control). While p53 expression was not affected, the expression
Brca1 gene by homologous recombination in mouse ESof mdm-2 was reduced in Brca15-6 mutant embryos. The L32 gene
cells. The Brca15-6 mutation drastically affects embry-was expressed equally in wild-type and mutant blastocysts. (C)
The expression of p21, weakly expressed in the E4 wild type, was onic growth and the differentiation of the diploid tropho-
dramatically increased in the E4 Brca15-6 mutant. blast tissue, resulting in lethality before day 7.5 of ges-
tation.
Our results contrast with the recent analysis of Brca1
mutant mice obtained by deletion of exon 11 (Gowen etthat are double mutants for mdm-2 and p53 are viable
(Jones et al., 1995; Montes de Oca Luna et al., 1995). al., 1996). These Brca1 exon 11 mutant mice survived
until midgestation, dying in utero between days 10 andBased on the phenotypic similarity between Brca15-6
and mdm-2 mutant mice and the effect of the 13 of development. The primary site of anomaly was the
neural tube, with mutants presenting varying degrees ofBrca15-6 mutation on cellular proliferation, we deter-
mined whether the Brca15-6 lethality could be due to spina bifida and anencephaly. In addition, these mutant
embryos showed both increased cellular proliferationchanges in mdm-2 or p53 expression. mdm-2 and p53
expression in Brca15-6 embryos was examined using 39 and cell death in the hindbrain neuroepithelium.
Previous studies have demonstrated the presence ofUTR probes in a Southern blot analysis of the total cDNA
generated from E2.5 and E4 wild-type and mutant em- several alternatively spliced forms of both human and
murine breast cancer 1 gene transcripts (Miki et al.,bryos. mdm-2 expression was found to be decreased
in mutant embryos, whereas the level of p53 appeared 1994; Lane et al., 1995; Marquis et al., 1995). A splice
variant of Brca1 that is missing exon 11 is coexpressedto be unaffected (Figures 7A and 7B).
Interestingly, the expression of a downstream effector at similar levels to the full-length Brca1 transcript in
most cells and tissues (Frank Calzone, personal commu-and transcription activation target for p53, the cyclin-
dependent kinase (cdk) inhibitor p21 (Gu et al., 1993; nication). We show here, in ES cells and during em-
bryogenesis, the coexpression of Brca1 exon 11 positiveHarper et al., 1993), was found to be dramatically in-
creased in the mutant E4 blastocyst cDNA (Figure 7C), and exon 11 negative transcripts. However, Brca1 exons
Cell
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Figure 8. Defective Growth of Mutant Brca15-6 Blastocysts In Vitro
(A) Wild-type E3.5 blastocyst. (B) Outgrowth after three days of culture. The inner cell mass (ICM) is surrounded by trophoblast giant cells
(TG). (C) Mutant E3.5 blastocyst. (D) Outgrowth after three days of culture. Only trophoblast giant cells have grown (no ICM growth). Bar, 20
mm in (A) and (C); 40 mm in (B) and (D).
5 and 6 are always present during embryogenesis, sug-
gesting that they are essential for Brca1 function atTable 2. Genotypic and Phenotypic Analysis of Brca15-6 Mutant
these stages. Thus, deletion of exons 5 and 6 resultsBlastocysts Cultured In Vitro
in the inactivation of Brca1 gene function. The weakerPhenotype
phenotype associated with the deletion of Brca1 exon
Genotype Total Number Normal Abnormal 11 could therefore result from incomplete inactivation
of the Brca1 gene due to alternative splicing of thisBrca11/1 13 11 (85%) 2 (15%)
Brca11/2 35 30 (86%) 5 (14%) exon during early embryogenesis. Alternative splicing
Brca12/2 12 7 (59%) 5 (41%) variants of other tumor suppressor genes have pre-
viously been reported to have different functions (En-Blastocysts at day 3.5 of gestation from Brca15-6 heterozygous inter-
crosses werecollected and individually cultured in ES media without glert et al., 1995).
LIF. Embryos grown in vitro for three days were photographed and
genotyped by PCR amplification using primers a, b, c, and d as
Brca1 and Trophoblast Differentiationshown in Figure 1. The embryo phenotype was scored as abnormal
Extraembryonic tissues play an important role in devel-when the ICM did not develop after three days in culture. Numbers
in parentheses indicate percentages of cultured blastocysts with opment from the very early stages, allowing the embryo
normal and abnormal phenotypes. Twenty-four blastocyst out- to attach to the uterus during implantation, and later
growths were recovered after 10 days in culture; only one was participating in the formation of the chorioallantoic pla-
Brca15-6, and it had not developed any ICM.
centa. Histological analysis of Brca15-6 mutant embryos
Brca1 Is Required for Embryonic Cell Proliferation
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at E6.5 revealed a poorly organized extraembryonic re- Lack of mesoderm formation has been previously ob-
served in other mutant embryos having defects in epi-gion. In addition, Mash-2, a transcription factor ex-
pressed at high levels in the diploid component of the blast proliferation. Mice mutant for Bmpr, a gene coding
for a protein member of the TGF-b superfamily receptor,trophoblast, was not expressed in Brca15-6 mutant em-
bryos. Mash-2 mutant mice die at day 10 of gestation but showed decreased epiblast cell proliferation at E6.5 and
no mesoderm formation (Mishina et al., 1995). At the timecan be rescued by providing wild-type extraembryonic
tissues (Guillemot et al., 1994). It was possible that the of gastrulation, E6.5 Brca15-6 mutant embryos showed a
severely abnormal phenotype, with no obvious meso-early death of the Brca15-6 mutant embryos could have
been due to abnormal development of the trophoblast. derm formation, and died shortly thereafter. The lack
of morphological differentiation of mesoderm in E6.5However, aggregation of Brca15-6 morulaswith wild-type
tetraploid embryos did not rescue their lethality. There- Brca15-6 mutants was confirmed by their failure to ex-
press Brachyury. Our dataare consistent with an indirectfore, abnormal trophoblast development is likely to be
a factor in, but not the sole cause of, lethality in Brca15-6 requirement for Brca1 in mesoderm development, re-
lated to its role in epiblast proliferation prior to the stagemutant embryos.
Interestingly, the polyploid trophoblast giant cells of gastrulation.
(which do not normally express Mash-2) appear to be
unaffected in Brca15-6 mutant embryos. The normal de-
Novel Role for Brca1velopment of these cells suggests that Brca1 might be
Cancers result from genetic lesions leading to uncon-exclusively involved in the differentiation of the diploid
trolled cell growth. Several tumor suppressor geneslineages of the trophoblast. Alternatively, the giant cells
have been cloned, and mutations of these genes havethat survive may be the primary giant cells that derive
been shown to be responsible for tumor development.from the blastocysts (Varmuza et al., 1988). It is possible
Inherited mutationsand loss of heterozygosity of BRCA1that a maternal supply of Brca1 protein or RNA is suffi-
have been shown in patients from families with earlycient to allow the generation of these early trophoblast
onset of breast and ovarian cancer. Transfection of thecells. Survival of the trophoblast giant cells has been
wild-type BRCA1 gene inhibits breast and ovarian can-observed in mice mutant for the Min allele of the tumor
cer cell growth but does not affect the proliferation ofsuppressor gene Apc. Min mutant embryos die at about
lung and colon cancer cells (Holt et al., 1996). Thus, inE7.5 and show a phenotype similar to that of Brca15-6
the adult, BRCA1 has a tissue-specific growth inhibitoryembryos, in that epiblast development is impaired and
function and acts as a tumor suppressor gene.only trophoblast giant cells survive after E7.5 (Moser et
Brca1 is highly expressed in proliferating mouse ESal., 1995).
cells and in activated proliferating splenocytes (data not
shown), suggesting that Brca1 might be acting in these
cells as a positive regulator of cell growth. Wild-typeBrca1 and Cellular Proliferation and Gastrulation
Gastrulation in the mouse embryo takes place at about E6.5 epiblast cells, which express Brca1, are actively
proliferating cells, whereas the Brca15-6 mutation causesday 6.5 of gestation, when the mesoderm is generated
from the epiblast. Gastrulation is associated with rapid a decrease in cellular proliferation. In addition, we were
unsuccessful in our attempts to obtain viable ES cellsepiblast cell proliferation. It has been reported that
1400–1500 cells must accumulate in the epiblast to initi- homozygous for the Brca15-6 mutation, supporting the
defect in cell growth identified in vivo and in vitro. Thus,ate this process (Power and Tam., 1993). A wild-type
embryo at E5.5 contains 120 epiblast cells, whereas at the Brca1 gene may play, at some developmental stages
and in specific tissues, a positive role in control of cellE6.5 and E7.5, this number increases to 660 and 14,290
cells, respectively (Snow, 1977). This dramatic increase growth.
We provide evidence suggesting that Brca1 mightin cell number correlates with a decrease in cell cycle
length from 11.5 hr at E5.5 to 4.4 hr at E6.5 of gestation. affect cell cycle regulation. p53 expression levels were
unaffected in Brca15-6 mutants, although expression ofA defect in Brca15-6 epiblast cell proliferation was
clearly defined by the BrdU incorporation analysis in mdm-2, a gene coding for a negative regulator of p53
activity, was reduced. Furthermore, the expression ofE6.5 Brca15-6 mutants. Our results indicate that cellular
proliferation was impaired quantitatively and qualita- p21, a G1 cell cycle transition inhibitor, was increased
in E4 and E6.5 Brca15-6 mutants. P21 is a universal cdktively. In addition, cyclin E expression was decreased
in Brca15-6 mutant embryos, further suggesting a defect inhibitor (Gu et al., 1993; Harper et al., 1993), and its
expression is directly regulated by p53 protein (El-Deiryin the ability of these cells to enter the S phase. If Brca1
plays a role in the control of cellular proliferation, its et al., 1993). Although the expression of p21 can be
induced by other regulatory signals, the decrease ininactivation should cause lethality at earlier develop-
mental stages. Nevertheless, E3.5 Brca15-6 blastocysts mdm-2 expression observed in Brca15-6 embryos sug-
gests that there could be an increase in p53 activityappeared normal, although their proliferative abilities in
vitro were dramatically reduced. Only giant cells sur- which could, in turn, increase p21 expression, causing
the impaired growth of the Brca15-6 mutants.vived after culture, suggesting that this lineage may be
less dependent on Brca1 protein. The in vivo survival Cyclin cdk complexes containing more than one p21
subunit are not catalytically active, suggesting that theof Brca15-6 mutant embryos until E6.5 could be due to
persistence of maternal Brca1 protein or mRNA that stoichiometry of p21 and cdk’s is important for the func-
tion of these complexes (Zhang et al., 1994). Transgenicpermits the development of the embryo until early gas-
trulation stages. mice overexpressing p21 in their hepatocytes showed
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with C57BL/6J females (Jackson Laboratories), and germline trans-a dramatic block in hepatocyte proliferation (Wu et al.,
mission of the mutant allele was verified by PCR and Southern blot1996). The in vivo effect of p21 overexpression in these
analysis of tail DNA from F1 offspring with agouti coat color. Twotransgenic mice was cell autonomous and did not lead
injected ES colonies contributed to the germline of mice. F2 off-
to an increase in apoptosis. As mentioned above, no spring from heterozygous intercrosses were genotyped by Southern
defect in apoptosis was observed in Brca15-6 mutant blotting. The heterozygous males were also crossed with CD1 and
C3H/HeJ females (Jackson Laboratories). Mutant mice derived frommice. Previous studies have suggested a role for p21
the two targeted ES cells showed the same phenotype.both in differentiation and in the inhibition of cellular
proliferation. However, p21 mutant mice were found to
PCR Analysis of Brca15-6 Genotypesdevelop normally, suggesting that p21 is not essential
Genomic DNA from ES cells and neonate tails was isolated and
for cell differentiation (Brugarolas et al., 1995; Deng et used in PCR amplification. Yolk sacs, E6.5, E7.5, E8.5 embryos, or
al., 1995). Thus, the increased p21 expression in the in vitro cultured blastocysts were incubated overnight at 378C in
Brca15-6 mutant embryos is more likely to have affected 100 ml of lysis buffer (50 mM KCL, 10 mM Tris (pH 8.3), 2 mM MgCl2,
0.1 mg/ml gelatin, 0.45% NP-40, and 0.45% Tween-20) containingcellular proliferation rather than differentiation.
10 mg/ml of proteinase K. After 10 min boiling, 1–5 ml of the samplesThe high level of p21, the low BrdU incorporation,
was subjected to PCR amplification. Primers “a” (59-GAT TTG GTCand persistent expression of cyclins in Brca15-6 mutant
TTT TTC CTC ACA-39) and “b” (59-CTT ATT GCA CTT ATT TAT
embryos are all strongly suggestive of a slowedprogres- TGG-39), specific for the targeted intronic sequence downstream of
sion through the cell cycle (or even a cell cycle block). Brca1 exon 6, were used to detect the wild-type allele, while the
In addition to these defects observed in vivo, growth of primers “c” and “d” (see above) were used to detect the recombinant
allele. Temperature cycling conditions were: one initial cycle at 948Cthe mutant embryos was also grossly retarded in vitro.
for 5 min, 598C for 5 min, and 728C for 2 min, followed by 40 cyclesThough unlikely, it remains a possibility that Brca1 muta-
at 948C for 30 s, 598C for 1 min, and 728C for 1 min. One-fifth oftion results in the expansion of a particular cell type that
each reaction mixture was electrophoresed on a 2% agarose gel
in turn exerts a negative growth effect on the embryos, and stained with ethidium bromide. Primer pair a/b amplified a 353
leading to lethality. bp fragment in the heterozygote and wild-type samples, whereas
In summary, our results demonstrate that Brca1 may the primer pair c/d amplified a 616bp fragment in both heterozygous
and homozygous DNA.be a positive regulator of cellular proliferation in early
embryogenesis. We also provide evidence supporting
RNA Analysisthe requirement of Brca1 for the cell cycle progression of
Total RNA was extracted from ES cells or E7.5, E8.5, E9.5, and E10.5embryonic cells, suggesting that Brca1 may be involved
using Trizol (Life Technologies). For Northern blot analysis, 10 mg
directly or indirectly in its regulation. Establishment of RNA were electrophoresed in a 1% agarose/formaldelhyde gel and
tissue-specific Brca1 mutations will help define the pre- transferred to a nylon membrane (Hybond N1, Amersham). RNA
cise function of Brca1 during oncogenesis and normal blots were hybridized overnight at 658C in Church and Gilbert buffer.
The filters were initially hybridized with either a 243 bp exon 11,development.
or a 248 bp exons 7–9, Brca1-specific probes, and subsequently
stripped and rehybridized with a mouse b-actin probe. Brca1 exon
Experimental Procedures 11 probe was amplified by PCRusing an upstream primer at position
1270 (59-AAG TGG ATG GGG GTT TTA GTT-39) and a downstream
Cells primer at position 1513 (59-TTA TTT GTG AAG GGC TGC TCT-39).
E14K embryonic stem cells from 129/Ola mice were maintained on Brca1 exons 7–9 probe was amplified using an upstream primer
a layer of mitomycin C–treated embryonic fibroblasts in Dulbecco’s at position 360 (59-AAT AAT TCT TGT GAG CGT TTG-39) and a
modified Eagle’s culture medium, supplemented with leukemia in- downstream primer at position 587 (59-CCT GGC TTA GTT ACT GCT
hibitory factor, 15% fetal calf serum, L-glutamine, and b-mercapto- TCT-39). RNA blots were washed in 23 SSC at room temperature
ethanol. for 15 min, followed by two washes in 23 SCC 0.1% SDS at 658C
for 30 min, and finally with 2 washes in 0.23 SCC 0.1% SDS at 658C
for 30 min.Generation of Brca15-6 Mutant Mice
cDNAs from ES and E7.5 cells were generated using randomA 129/J mouse genomic library was screened with an exon 11
primers and reagents from Amersham. PCR amplification of Brca1BRCA1 human probe made by PCR amplification using primers at
exons 3–7 was performed using an exon 3 upstream primer at posi-positions 1161 and 1981 (59-TGT GAG AGA AAA GAA TGG AAT-39
tion 111 (59-GAA CTG ATC AAA GAA CCT GTT-39’) and an exon 7and 59-TGA ATA TGC CTG GTA GAA GAC-39). Five overlapping
downstream primer at position 418 (59-GAA GCC TTC TGA CACphage genomic clones containing exons 5–13 were isolated. A tar-
GGT TCC-39). PCR amplification of Brca1 exons 9–13 was performedgeting vector was designed to replace a 3.3 kb genomic fragment
using an exon 9 upstream primer at position 593 (59-AGT AAC TAAcontaining exons 5 and 6 with the PGKneo resistance expression
GCC AGG TGA TTG-39) and an exon 13 downstream primer at posi-cassette in reverse orientation to Brca1 transcription. The targeting
tion 4225 (59-CTG ACA TGTTTG GTTCCA GAT-39). Oligonucleotidesvector (20 mg) was linearized with KpnI and electroporated into (5 3
used for the Brca1 PCR Southern blot hybridization were: an106) E14K ES cells (Bio-Rad Gene Pulser, 0.34 kV, 0.25 mF). The
exon 5 specific primer (59-TTT GTA TGC TGA AAC TTC TTA-39), ancells were subsequently cultured in the presence of 300 mg/ml of
exon 6 specific primer (59-CAA GCT CAA AAG CAG CCA TTA-39),G418 (Sigma) for 10 days. Homologous recombinantswere identified
an exon 10 specific primer (59-TGT TAC AGA CCG CCC CTCby PCR. An external primer “c” specific for the Brca1 gene upstream
AAG-39), and an exon 12 specific primer (59-GCG AGC AGT CTTof the targeting construct (59-TCC TTT GGT TTA GCA CCT ACT-39)
CAG AAA GGT-39).and a primer “d” specific for the neomycin resistance gene cassette
(59-CCA GCT CAT TCC TCC CAC TCA T-39) were used in the PCR
analysis. Colonies positive by PCR were genotyped by Southern Amplification of Total cDNA in the Preimplantation Embryos
Embryos at day 2.5 and day 4 of gestation were collected fromblotting of HindIII digested DNA and hybridized with random hex-
amer 32P-dCTP-labeled DNA probes (Amersham). A HindIII–KpnI 378 heterozygous crosses, and total cDNA was amplified following a
protocol previously described for single cell PCR (Brady et al., 1990).bp Brca1 external probe and a neomycin–specific probe were used
for hybridization. Four correct targeted colonies were identified. In brief, individual embryos were lysed at room temperature for 20
min in 6 ml of first strand buffer (5 mM Tris–HCL [pH 8.3], 75 mMChimeric mice were produced by microinjection of targeted ES
cells into 3.5-day C57BL/6J blastocysts that were transferred to KCL, 3 mM MgCl2, 2 mM of each dNTP, 100 ng/ml (dT)24, 100 U/ml
Inhibit Ace [59-39 Inc.], 2000 U/ml RNAguard [Pharmacia], and 0.5%CD1 pseudopregnant foster mothers. Chimeric males were mated
Brca1 Is Required for Embryonic Cell Proliferation
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NP-40). The nuclei were recovered by centrifugation at 12,000 g for quenched by incubating the sections for 40 min in methanol con-
taining 1% H2O2. Sections were incubated for 5 hrs at room tempera-50 s, and 4 ml of the supernatant were used to generate the total
cDNA. The nuclei were lysed in 10 ml of water by heating the samples ture with the primary antibody, 1 hr with goat anti-rabbit IgG, and
1 hr with avidin–peroxidase complex, at room temperature. Theat 958C for 2 min, and 1/5 of the sample was used to genotype the
embryos by PCR using the primers a/b and c/d described above. signal was visualized in 30–60 min by an horseradish peroxidase
reaction (Vector Laboratories) using diaminobenzidine (DAB, 1 mg/For most embryos, a second round of PCR was required to detect
a PCR product using nested primers. The remaining supernatant ml in 0.1 M Tris–HCl [pH 7.5]) and hydrogen peroxide (0.03% final)
as substrates. To enhance the signal, NiCl2 (0.04% final) was usedwas heated at 658C for 1 min, cooled at 228C for 3 min, and returned
to ice. The poly(A) mRNA present in the supernatant was then oli- in the developer cocktail.
go(dT)-primed and converted to cDNA with 100 U Moloney (GIBCO–
BRL) and 2 U avian reverse transcriptase (Boehringer/Mannheim) BrdU Labeling of Embryos
by incubating the samples at 378C for 15 min. The reaction was BrdU labeling of cells in the S phase of the cell cycle was performed
terminated by heat inactivation of the enzymes at 658C for 10 min, according to the protocol described by Hayashi et al. (1988). BrdU
and returned to ice. These conditions limit the length of the cDNAs (100 mg per gram of body weight) was injected intraperitoneally into
generated to between 300 to 700 bases. Total cDNA was tailed with pregnant females at E6.5. The females were sacrificed 1 hr after
oligo(dA) using terminal transferase followed by PCR amplification injection, the uteri were removed, and the decidual swellings were
using an oligo(dT) primer. This process generates an almost unlim- fixed in 4% paraformaldehyde at 48C overnight and processed for
ited source of cDNA and results in the unbiased amplification of immunohistochemistry. The sections were incubated with an anti-
cDNAs representing all polyadenylated RNAs present in the sample. BrdU monoclonal antibody (Boehringer Mannheim) at a 1:10 dilution.
The expression of any gene can be assessed by Southern blotting Staining was performed according to the protocol described by
of the PCR reaction using probes prepared by PCR amplification Mishina et al. (1995).
of the 39 untranslated region of the gene tested.
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